With help from Lululemon founder’s venture philanthropy, Vita adds second muscular dystrophy indication to lineup

Lei Lei Wu

News Reporter

Earlier this year, Lululemon’s founder Chip Wilson went public with his rare disease diagnosis of facioscapulohumeral muscular dystrophy type 2, or FSHD type 2, in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With help from Lululemon founder’s venture philanthropy, Vita adds second muscular dystrophy indication to lineup

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Zealand’s ‘aspirational’ mission for its amylin drug to be first-line in obesity

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

J&J's Darzalex hits primary endpoint in Phase 3 early-stage multiple myeloma trial

Vertex makes money from sickle cell therapy Casgevy

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

With help from Lu­l­ule­mon founder’s ven­ture phil­an­thropy, Vi­ta adds sec­ond mus­cu­lar dy­s­tro­phy in­di­ca­tion to line­up

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

With help from Lululemon founder’s venture philanthropy, Vita adds second muscular dystrophy indication to lineup